Ativan Lorazepam Injection Recalled Nationwide for Out-of-Specification Impurities
Nationwide recall of Ativan (lorazepam) injection lot 060064Z due to out-of-specification impurities and degradation products. Patients should contact their healthcare provider.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard (out-of-specification impurities and degradation products) is a quality issue addressed through precautionary recall, not a confirmed safety incident with actual harm reported.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling Ativan (lorazepam) injection, 2mg/mL, supplied in 1 mL vials packaged 25 vials per carton, distributed nationwide. The affected lot is 060064Z, with an expiration date of June 2023. The recall involves 301,400 vials total.
The recall was initiated following testing failures. Laboratory testing of retained samples revealed out-of-specification results for total related compounds. Impurities and degradation products in the samples exceeded acceptable limits.
Ativan injection is a prescription benzodiazepine. Patients who received medication from the recalled lot should contact their healthcare provider.
Healthcare providers should review patient records to identify if doses from the affected lot were administered and take appropriate action, including patient notification.
The recalled product
- Product
- ATIVAN (LORAZEPAM)
- Brand
- ATIVAN
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug — Injectable Benzodiazepine
- Hazard
- degradation-products
- impurities
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 060064Z
- Exp. 06/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27